Deep brain stimulation (DBS) has emerged as a promising intervention for severe, treatment-resistant psychiatric disorders such as obsessive-compulsive disorder (OCD) and treatment-resistant depression (TRD), where conventional therapies often fail. Despite overlapping neurocircuitry, the clinical trajectories and translational challenges of these conditions differ substantially. This review examines the current evidence and advancements in DBS for severe, treatment-resistant psychiatric disorders.
Methods
A literature search was conducted to identify relevant studies on DBS for OCD and TRD. The search was performed in PubMed and Google Scholar, covering publications from 2020 to 2025. Older studies were included if deemed essential references. Keywords and Boolean combinations such as “DBS,” “deep brain stimulation,” “OCD,” “TRD,” “treatment-resistant depression,” and “psychiatric neuromodulation” were used to refine the search and enhance specificity.
Results
Clinical findings demonstrate sustained long-term benefits of DBS in OCD, although recent sham-controlled trials report smaller effect sizes than earlier open-label studies. In TRD, outcomes remain inconsistent, with open-label trials showing high response rates but larger randomised trials failing to significantly outperform sham stimulation. Emerging innovations include connectomic-guided targeting, AI-assisted predictive models, and closed-loop DBS systems driven by neural biomarkers.
Conclusion
DBS remains a promising therapy for refractory OCD and TRD. Future progress depends on addressing methodological, ethical, and translational challenges while advancing personalised, data-driven neuromodulation strategies.
RuscioAMSteinDJChiuWTKesslerRC. The epidemiology of obsessive-compulsive disorder in the national comorbidity survey replication. Mol Psychiatr. 2010;15(1):53-63. 20080826. doi:10.1038/mp.2008.94.
2.
HuangYWangYWangH, et al.Prevalence of mental disorders in China: a cross-sectional epidemiological study. Lancet Psychiatry. 2019;6:211-224. 20190218. doi:10.1016/s2215-0366(18)30511-x.
RushAJTrivediMHWisniewskiSR, et al.Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatr. 2006;163:1905-1917. doi:10.1176/ajp.2006.163.11.1905.
5.
FekaduAWoodersonSCMarkopouloKDonaldsonCPapadopoulosACleareAJ. What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies. J Affect Disord. 2009;116:4-11. 20081112. doi:10.1016/j.jad.2008.10.014.
6.
DrevetsWCPriceJLFureyML. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct. 2008;213:93-118. 20080813. doi:10.1007/s00429-008-0189-x.
7.
MalletLPolosanMJaafariN, et al.Subthalamic nucleus stimulation in severe obsessive-compulsive disorder. N Engl J Med. 2008;359:2121-2134. doi:10.1056/NEJMoa0708514.
BenabidAL. Deep brain stimulation for parkinson's disease. Curr Opin Neurobiol. 2003;13:696-706. doi:10.1016/j.conb.2003.11.001.
10.
GardnerJ. A history of deep brain stimulation: technological innovation and the role of clinical assessment tools. Soc Stud Sci. 2013;43:707-728. doi:10.1177/0306312713483678.
11.
WidgeASZorowitzSBasuI, et al.Deep brain stimulation of the internal capsule enhances human cognitive control and prefrontal cortex function. Nat Commun. 2019;10:1536:20190404. doi:10.1038/s41467-019-09557-4.
12.
NuttinBCosynsPDemeulemeesterHGybelsJMeyersonB. Electrical stimulation in anterior limbs of internal capsules in patients with obsessive-compulsive disorder. Lancet. 1999;354:1526. doi:10.1016/s0140-6736(99)02376-4.
13.
FigeeMRiva-PossePChoiKSBedersonLMaybergHSKopellBH. Deep brain stimulation for depression. Neurotherapeutics. 2022;19:1229-1245. 20220711. doi:10.1007/s13311-022-01270-3.
14.
GreenbergBDGabrielsLAMaloneDAJr., et al.Deep brain stimulation of the ventral internal capsule/ventral striatum for obsessive-compulsive disorder: worldwide experience. Mol Psychiatr. 2010;15:64-79. 20080520. doi:10.1038/mp.2008.55.
15.
MithaniKDavisonBMengYLipsmanN. The anterior limb of the internal capsule: anatomy, function, and dysfunction. Behav Brain Res. 2020;387:112588. 20200314. doi:10.1016/j.bbr.2020.112588.
16.
SturmVLenartzDKoulousakisA, et al.The nucleus accumbens: a target for deep brain stimulation in obsessive-compulsive- and anxiety-disorders. J Chem Neuroanat. 2003;26:293-299. doi:10.1016/j.jchemneu.2003.09.003.
17.
Mar-BarrutiaLIbarrondoOMarJ, et al.Long-term comparative effectiveness of deep brain stimulation in severe obsessive-compulsive disorder. Brain Stimul. 2022;15:1128-1138. 20220801. doi:10.1016/j.brs.2022.07.050.
18.
MaybergHSLozanoAMVoonV, et al.Deep brain stimulation for treatment-resistant depression. Neuron. 2005;45:651-660. doi:10.1016/j.neuron.2005.02.014.
19.
CoenenVASchlaepferTEGollP, et al.The medial forebrain bundle as a target for deep brain stimulation for obsessive-compulsive disorder. CNS Spectr. 2017;22:282-289. 20160608. doi:10.1017/s1092852916000286.
20.
AlagapanSChoiKSHeisigS, et al.Cingulate dynamics track depression recovery with deep brain stimulation. Nature. 2023;622:130-138. 20230920. doi:10.1038/s41586-023-06541-3.
21.
ProvenzaNRReddySAllamAK, et al.Disruption of neural periodicity predicts clinical response after deep brain stimulation for obsessive-compulsive disorder. Nat Med. 2024;30:3004-3014. doi:10.1038/s41591-024-03125-0.
22.
PezawasLMeyer-LindenbergADrabantEM, et al.5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. Nat Neurosci. 2005;8:828-834. 20050508. doi:10.1038/nn1463.
GattJMNemeroffCBDobson-StoneC, et al.Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathways to syndromal depression and anxiety. Mol Psychiatr. 2009;14:681-695. 20090120. doi:10.1038/mp.2008.143.
25.
VanesLDDolanRJ. Transdiagnostic neuroimaging markers of psychiatric risk: a narrative review. Neuroimage, Clin. 2021;30:102634. 20210317. doi:10.1016/j.nicl.2021.102634.
26.
SartoriusAKieningKLKirschP, et al.Remission of major depression under deep brain stimulation of the lateral habenula in a therapy-refractory patient. Biol Psychiatry. 2010;67:e9-e11. doi:10.1016/j.biopsych.2009.08.027.
27.
DenysDGraatIMockingR, et al.Efficacy of deep brain stimulation of the ventral anterior limb of the internal capsule for refractory obsessive-compulsive disorder: a clinical cohort of 70 patients. Am J Psychiatr. 2020;177:265-271. 20200107. doi:10.1176/appi.ajp.2019.19060656.
28.
CohenSENiemeijerMJZantvoordJBvan WingenGAMockingRJTDenysD. Deep brain stimulation for obsessive-compulsive-disorder: a systematic review and meta-analysis of individual participant outcome data from sham-controlled trials. Mol Psychiatr. 2025;30:4937-4947. 20250627. doi:10.1038/s41380-025-03092-z.
29.
GraatIMockingRJTLiebrandLC, et al.Tractography-based versus anatomical landmark-based targeting in vALIC deep brain stimulation for refractory obsessive-compulsive disorder. Mol Psychiatr. 2022;27:5206-5212. 20220907. doi:10.1038/s41380-022-01760-y.
30.
Riva-PossePChoiKSHoltzheimerPE, et al.A connectomic approach for subcallosal cingulate deep brain stimulation surgery: prospective targeting in treatment-resistant depression. Mol Psychiatr. 2018;23:843-849. 20170411. doi:10.1038/mp.2017.59.
31.
ConnerCRQuevedoJSoaresJCFenoyAJ. Brain metabolic changes and clinical response to superolateral medial forebrain bundle deep brain stimulation for treatment-resistant depression. Mol Psychiatr. 2022;27:4561-4567. doi:10.1038/s41380-022-01726-0.
32.
CoenenVABewernickBHKayserS, et al.Superolateral medial forebrain bundle deep brain stimulation in major depression: a gateway trial. Neuropsychopharmacology. 2019;44:1224-1232. 20190313. doi:10.1038/s41386-019-0369-9.
33.
DoughertyDDRezaiARCarpenterLL, et al.A randomized sham-controlled trial of deep brain stimulation of the ventral capsule/ventral striatum for chronic treatment-resistant depression. Biol Psychiatry. 2015;78:240-248. 20141213. doi:10.1016/j.biopsych.2014.11.023.
34.
ReddySKabotyanskiKEHiraniS, et al.Efficacy of deep brain stimulation for treatment-resistant depression: systematic review and meta-analysis. Biol Psychiatry Cogn Neurosci Neuroimaging. 2024;9:1239-1248. 20240826. doi:10.1016/j.bpsc.2024.08.013.
35.
RuniaNMolGJJDenysD, et al.Deep brain stimulation improves symptoms across all dimensions in treatment-resistant depression. Neurotherapeutics. 2025;22(20250610):e00623. doi:10.1016/j.neurot.2025.e00623.
36.
ScangosKWMakhoulGSSugrueLPChangEFKrystalAD. State-dependent responses to intracranial brain stimulation in a patient with depression. Nat Med. 2021;27:229-231. doi:10.1038/s41591-020-01175-8.
37.
BergfeldIOOomsPLokA, et al.Efficacy and quality of life after 6-9 years of deep brain stimulation for depression. Brain Stimul. 2022;15:957-964. 20220627. doi:10.1016/j.brs.2022.06.010.
38.
van der WalJMBergfeldIOLokA, et al.Long-term deep brain stimulation of the ventral anterior limb of the internal capsule for treatment-resistant depression. J Neurol Neurosurg Psychiatry. 2020;91:189-195. 20191204. doi:10.1136/jnnp-2019-321758.
39.
Mar-BarrutiaLRealESegalásCBertolínSMenchónJMAlonsoP. Deep brain stimulation for obsessive-compulsive disorder: a systematic review of worldwide experience after 20 years. World J Psychiatr. 2021;11:659-680. 20210919. doi:10.5498/wjp.v11.i9.659.
40.
KabotyanskiKENajeraRABanksGP, et al.Cost-effectiveness and threshold analysis of deep brain stimulation vs. treatment-as-usual for treatment-resistant depression. Transl Psychiatry. 2024;14:243:20240607. doi:10.1038/s41398-024-02951-7.
41.
AssociationWM. World medical association declaration of helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191-2194. doi:10.1001/jama.2013.281053.
42.
MuñozKAKostickKSanchezC, et al.Researcher perspectives on ethical considerations in adaptive deep brain stimulation trials. Front Hum Neurosci. 2020;14:578695. 20201112. doi:10.3389/fnhum.2020.578695.
43.
PriceMZPriceRL. Benefits and risks of esketamine nasal spray continuation in treatment-resistant depression. Biomarkers in Neuropsychiatry. 2024;11:100104. doi:10.1016/j.bionps.2024.100104.
44.
MedeirosGCDemoIGoesFSZarateCAJrGouldTD. Personalized use of ketamine and esketamine for treatment-resistant depression. Transl Psychiatry. 2024;14:481. doi:10.1038/s41398-024-03180-8.
45.
BorissovaARuckerJJ. The development of psilocybin therapy for treatment-resistant depression: an update. BJPsych Bull. 2024;48:38-44. doi:10.1192/bjb.2023.25.
46.
MetaxaAMClarkeM. Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis. BMJ. 2024;385:e078084. 20240501. doi:10.1136/bmj-2023-078084.
47.
VidaRGSághyEBellaR, et al.Efficacy of repetitive transcranial magnetic stimulation (rTMS) adjunctive therapy for major depressive disorder (MDD) after two antidepressant treatment failures: meta-analysis of randomized sham-controlled trials. BMC Psychiatry. 2023;23:545:20230727. doi:10.1186/s12888-023-05033-y.
48.
ParkYSSammartinoFYoungNACorriganJKrishnaVRezaiAR. Anatomic review of the ventral capsule/ventral striatum and the nucleus accumbens to guide target selection for deep brain stimulation for obsessive-compulsive disorder. World Neurosurg. 2019;126:1-10. 20190218. doi:10.1016/j.wneu.2019.01.254.
49.
MalletLSchüpbachMN'DiayeK, et al.Stimulation of subterritories of the subthalamic nucleus reveals its role in the integration of the emotional and motor aspects of behavior. Proc Natl Acad Sci U S A. 2007;104:10661-10666. 20070607. doi:10.1073/pnas.0610849104.
50.
SchwabeKAlamMSaryyevaA, et al.Oscillatory activity in the BNST/ALIC and the frontal cortex in OCD: acute effects of DBS. J Neural Transm. 2021;128:215-224. 20210203. doi:10.1007/s00702-020-02297-6.
51.
GuzickAHuntPJBijankiKR, et al.Improving long term patient outcomes from deep brain stimulation for treatment-refractory obsessive-compulsive disorder. Expert Rev Neurother. 2020;20:95-107. 20191122. doi:10.1080/14737175.2020.1694409.
52.
TiefenbachJFavi BoccaLHogueONeroNBakerKBMachadoAG. Intracranial bleeding in deep brain stimulation surgery: a systematic review and meta-analysis. Stereotact Funct Neurosurg. 2023;101:207-216. doi:10.1159/000530398.
53.
TabajaHYuenJTaiDBG, et al.Deep brain stimulator device infection: the Mayo clinic Rochester experience. Open Forum Infect Dis. 2022;10:ofac631. doi:10.1093/ofid/ofac631.
54.
NurimanovCMammadinovaIMenlibayevaK, et al.Managing lead fractures in deep brain stimulation for movement disorders: a decade-long case series from a national neurosurgical centre. J Clin Med. 2024;13:20241210. doi:10.3390/jcm13247509.
55.
ChabardesSKrackPPiallatB, et al.Deep brain stimulation of the subthalamic nucleus in obsessive-compulsives disorders: long-term follow-up of an open, prospective, observational cohort. J Neurol Neurosurg Psychiatry. 2020;91:1349-1356. 20201008. doi:10.1136/jnnp-2020-323421.
